<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 10-Apr | 06:00 - 07:00 AM | Best Practices in Establishing Value in Laboratory Testing | Bio-Rad Unity as a Solution for Molecular Quality Control Data Management               | Duane W. Newton, PhD, D(ABMM), FIDSA  
Director, Clinical Microbiology Laboratory, Associate Director, Division of Clinical Pathology, Professor of Pathology, University of Michigan |
| 10-Apr | 06:00 - 07:00 AM | Disruptive Molecular Technologies          | Keynote Presentation: Nucleic Acid Detection with CRISPR Diagnostics                   | Omar Abudayyeh, PhD  
MIT McGovern Institute Fellow  
Jonathan Gootenberg, PhD  
MIT McGovern Institute Fellow, Massachusetts Institute of Technology |
| 10-Apr | 07:30 - 08:30 AM | Best Practices in Establishing Value in Laboratory Testing | Keynote Presentation: Clinical Lab 2.0 - How Laboratories Can Thrive in a Value Based Care System | Michael Crosse, MD, PhD  
Chief Executive Officer and Chief Medical Officer, TriCore Reference Laboratories |
| 10-Apr | 09:00 - 10:00 AM | Disruptive Molecular Technologies          | CRISPR Proteins: Enabling the Next-Generation of Molecular Diagnostics                 | James Broughton  
Senior Scientist, Mammoth Biosciences |
| 10-Apr | 09:00 - 10:00 AM | Disruptive Molecular Technologies          | Novel Applications of Molecular Diagnostics in Infectious Diseases                     | Esther Babady, PhD  
Director of Clinical Operations, Microbiology Service, Associate Attending Microbiologist, Departments of Medicine and Laboratory Medicine, Memorial Sloan Kettering Cancer Center |
| 10-Apr | 09:00 - 10:00 AM | Best Practices in Establishing Value in Laboratory Testing | Validation and Implementation of Quantitative Molecular Assays                           | Morgan A. Pence, PhD, D(ABMM)  
Director, Clinical and Molecular Microbiology, Cook Children's Medical Center |
| 10-Apr | 10:30 - 11:30 AM | Disruptive Molecular Technologies          | A Sample to Insight Solution for Detection and Classification of Challenging Pathogenic BRCA Mutations | Anika Joecker, PhD  
Associate Director Global Product Management NGS, QIAGEN  
Jennifer Poitras, PhD  
Principal Genome Scientist, Bioinformatics - Genetic Disease, QIAGEN |
| 10-Apr | 10:30 - 11:30 AM | Digital Diagnostics and Artificial Intelligence | Better Knowledge, Better Care: Precision Medicine for Any Cancer, Any Assay, on Your Platform | Sheryl Elkin, PhD  
Chief Scientific Officer, N-of-One, A QIAGEN Company  
Dan Richards, PhD  
Vice President, Biomedical Informatics, QIAGEN |
| 10-Apr | 10:30 - 11:30 AM | Disruptive Molecular Technologies          | CRISPR-Chip: Detection of Unamplified Target Genes via CRISPR/Cas9 Immobilized on a Graphene Biosensors | Kiana Aran, PhD  
Co-Founder, Nanosens, Assistant Professor of Biomedical Sciences at Keck Graduate Institute, Visiting Assistant Professor at UC Berkeley |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 10-Apr| 12:00 - 01:00 PM | Best Practices in Establishing Value in Laboratory Testing                    | Tony Magliocco, MD  
Executive Director of the Advanced Diagnostic Laboratories, Moffitt Cancer Center  
Keith Gligorich, PhD  
Laboratory Operations Director, Navican Precision Cancer Care |
| 10-Apr| 12:00 - 01:00 PM | Disruptive Molecular Technologies                                               | Brett Goldsmith, PhD  
CTO, Cardea |
| 10-Apr| 12:00 - 01:00 PM | Disruptive Molecular Technologies                                               | Shidong Jia, MD, PhD  
CEO, Predicine |
| 10-Apr| 01:30 - 02:30 PM | Detection and Interpretation of Complex Myeloid Leukemia Mutations             | Véronique Laloux, PhD  
Senior Global Product Manager of Personalized Healthcare/Oncology at QIAGEN  
Beate Litzenburger, PhD  
Product Owner of QIAGEN Clinical Insight (QCIâ„¢) Intepret |
| 10-Apr| 01:30 - 02:30 PM | Laboratory Medicine Beyond The Box: Value Based Health Care & Diagnostic Evidence | Elizabeth Marlowe, PhD, D(ABMM)  
Global Director of Medical Affairs, Microbiology, Roche Molecular Systems  
Joanna Sickler, MPH, MBA  
Director of Medical Affairs, Point-of-Care, Roche Molecular Systems |
| 10-Apr| 01:30 - 02:30 PM | Tools & Processes for Making Evidence-Based Policy Decisions                   | Eugean Jiwanmall, MPH, MBA  
Senior Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross |